Healthcare Industry News: Berlex
News Release - December 5, 2011
INSYS Therapeutics Announces Addition of VP of Marketing to Commercial TeamPHOENIX, AZ--(Healthcare Sales & Marketing Network)-- INSYS Therapeutics (Pinksheets: NEOL.PK ) announces the addition of Matthew Napoletano as Vice President of Marketing to their commercial product team. He will lead the strategic and tactical marketing initiatives in preparation for the launch of INSYS' breakthrough cancer pain product candidate, SubsysŪ fentanyl sublingual spray.
Michael Babich, President and CEO of INSYS, adds, "We are delighted to add an individual with such depth in the area of pain management and supportive care to our team as we continue to expand our commercial focus."
About INSYS Therapeutics, Inc.
INSYS Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative products that address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders. We develop new formulations and delivery methods for existing drugs in order to achieve enhanced efficacy, faster onset of action, reduced side effects, convenient delivery and increased patient compliance. Our drug development programs are based on existing compounds with known or proven safety, efficacy and commercialization histories. We are focused on leveraging our expertise in the expanding synthetic cannabinoid derivatives and specialized opioid markets to build a portfolio of proprietary products that address the limitations of existing therapies.
Source: INSYS Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.